Trial · NCT01485185
Gabapentin and Donepezil Combination on Experimental Human Pain Models
NCT01485185, Phase 1, Completed, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gabapentin and Donepezil Combination on Experimental Human Pain Models. Trials, record NCT01485185. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01485185
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gabapentin and Donepezil Combination on Experimental Human Pain Models
- NCT number
- NCT01485185
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 48 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Pain, Neuropathic
- Interventions
- Gabapentin lower dose, Donepezil, Placebo (Dop), Placebo (Gaba), Gabapentin higher dose
- First posted
- 2011-12-05
- Last updated
- 2017-06-12
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Area of pin-prick hyperalgesia | Change from baseline visit to day 14 of treatment sessions | Change in Area between treatment arms (compared to baseline), measured during the electrical hyperalgesia model using 26 Milli Neuton(mN) von Frey filament |
| Primary | Area of touch-evoked allodynia | Change from baseline visit to day 14 of treatment sessions | Change in Area between treatment arms (compared to baseline), measured during the electrical hyperalgesia model using a cotton bud |
| Secondary | Pain threshold | Change from baseline visit to day 14 of treatment sessions | Change in threshold between treatment arms (compared to baseline), measured from single electrical stimulation of sural nerve |
| Secondary | Ongoing pain intensity rating | Change from baseline visit to day 14 of treatment sessions | Change in intensity between treatment arms (compared to baseline), measured from 11-point numeric rating scale (NRS) where 0=no pain, 10=maximum pain imaginable |
| Secondary | Pain Tolerance | Change from baseline visit to day 14 of treatment sessions | Change in tolerance between treatment arms(compared to baseline), measured from single electrical stimulation of sural nerve |
| Secondary | Pain Temporal Summation | Change from baseline visit to day 14 of treatment sessions | Change in temporal summation between treatment arms (compared to baseline), measured from repetitive electrical stimulation of sural nerve |
| Secondary | Intensity of flare | Change from baseline visit to day 14 of treatment sessions | Change in intensity between treatment arms (compared to baseline), measured from Laser Doppler imaging evoked by electrical hyperalgesia model |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25218827 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01485185
GET https://conductscience.org/api/trials/v1/NCT01485185/registered